Program
pitavastatin
Also written as “Pitavastatin”, “Pitavastatin (NK-104)” and “NK-104-CR”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Dyslipidemias · Diabetes Mellitus, Type 2, led by 5 companies.
Drug pagePitavastatin: every studyMany companies study it; this page follows only the 29 they lead. All 75 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kowaits history only | 180 open or running | phase 4since Dec 18, 2009 | Nov 4, 2005 | none ahead |
| JW Pharmaceuticalits history only | 80 open or running | phase 4since Mar 18, 2008 | Mar 18, 2008 | none ahead |
| Merck | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| Orient Pharmaits history only | 10 open or running | phase 3since Oct 16, 2012 | Oct 16, 2012 | none ahead |
| Tai Tien Pharmaceuticalsits history only | 10 open or running | phase 3since Jun 29, 2011 | Jun 29, 2011 | none ahead |
Also a collaborator on its studies: Orient Europharma, Kowa Pharmaceuticals America and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 12, 2017First study: phase 1 study in Renal InsufficiencyFirst studyNCT03311841 · 32 enrolled · United States
TargetBeta
“HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03311841Renal Insufficiency · United States | 1 | Completed | Aug 2, 2018 | 32 |
How it is read
Names in the registry
- “Pitavastatin”, 18 entries
- “pitavastatin”, 8 entries
- “Pitavastatin (NK-104)”, 3 entries
- “NK-104-CR”, 2 entries
- “pitavastatin single dose combined with ceftobiprole”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 13 studies
- Hyperlipidemias, 5 studies
- Renal Insufficiency, 2 studies
- Dyslipidemias, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.